Benign prostatic hyperplasia and prostate cancer

Epidemiologic Reviews

Volumn 23, Issue 1, 2001, Pages 152-158

  Guess, Harry A ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; DISEASE ASSOCIATION; DISEASE COURSE; ENDOCRINE SYSTEM; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW; STROMA; SYMPTOMATOLOGY;

EID: 0034812525     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a000782     Document Type: Review

References (94)

1. Benign prostatic hyperplasia: Antecedents and natural history
2. Prostate cancer: A current perspective
3. Prostate cancer
4. Etiology of benign prostatic hyperplasia
5. The natural history of benign prostatic hyperplasia
6. Epidemiology of benign prostatic hyperplasia
7. Epidemiology and natural history of prostate cancer
8. Cancer of the prostate among men with benign prostatic hyperplasia
9. Relation between benign prostatic hyperplasia and cancer of the prostate: A prospective and retrospective study
10. Do prostate size and urinary flow rates predict health care seeking behavior for urinary symptoms in men?
11. The relation of surgery for prostatic hypertrophy to carcinoma of the prostate
12. The anatomic heterogeneity of the prostate
13. Normal histology of the prostate
14. Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern and direction of spread
15. Pathology of benign prostatic hyperplasia
16. Origin and evolution of benign prostatic enlargement
17. The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma: An update
18. Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern and direction of spread
19. The association of benign prostatic hyperplasia and cancer of the prostate
20. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate
21. Zonal origin of prostatic adenocarcinoma: Are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland?
22. The relationship between prostatic intraepithelial neoplasia and prostate cancer: Critical issues
23. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsies
24. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma
25. Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate
26. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate
27. Atypical adenomatous hyperplasia of the prostate: Relationship with carcinoma in 217 whole-mount radical prostatectomies
28. Adenosis (atypical adenomatous hyperplasia): Histopathology and relationship to carcinoma
29. Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia
30. Atypical adenomatous hyperplasia of the prostate: A premalignant lesion?
31. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia
32. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer
33. Hormonal signaling in prostatic hyperplasia and neoplasia
34. Androgen suppression in the management of benign prostatic hyperplasia
35. The effect of finasteride in men with benign prostatic hyperplasia
36. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
37. Design of the Prostate Cancer Prevention Trial (PCPT)
38. Dynamics of androgen and oestrogen secretion
39. The pathogenesis of benign prostatic hyperplasia
40. Endocrinology of the prostate
41. The regulation of prostatic growth
42. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture
43. Selective inhibition of steroid five-α-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate
44. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate
45. Molecular control of prostate growth
46. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men - Results of community-based studies in two countries
47. Keratinocyte growth factor: An androgen-regulated mediator of stromal-epithelial interactions in the prostate
48. Molecular biology of prostate growth regulation
49. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study
50. Transforming growth factor-β in benign and malignant prostate
51. Role of transforming growth factor-β signaling in cancer
52. Apoptosis and benign prostatic hyperplasia
53. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia
54. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation
55. Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH), and adenocarcinoma and have a high potential for predicting BPH and prostate cancer
56. 1H magnetic resonance spectra
57. Stem cell features of benign and malignant prostate epithelial cells
58. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells
59. Telomerase activity: A prevalent marker of malignant human prostate tissue
60. Etiology and disease process of benign prostatic hyperplasia
61. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model
62. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
63. PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia
64. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia
65. What is the "normal range" for prostate specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker
66. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer
67. Prostate specific antigen: A decade of discovery - What have we learned and where are we going
68. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
69. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer
70. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/mL
71. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
72. The American Cancer Society national prostate cancer detection project in 2425 men
73. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multi-center clinical trial of 6,630 men
74. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
75. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study
76. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
77. A population-based study of health care-seeking behavior for treatment of urinary symptoms
78. Early detection of prostate cancer: Serendipity strikes again
79. Today men with prostate cancer have larger prostates
80. The TNM system of 1992 - Comments from the THM working group
81. Latent carcinoma of prostate at autopsy in seven areas
82. Geographic pathology of latent prostatic carcinoma
83. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status
84. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
85. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old
86. The American Urological Association symptom index for benign prostatic hyperplasia
87. Results of an epidemiological survey employing a modified American Urological Association Index for benign prostatic hyperplasia in France
88. Adaptation and cultural validation in French language of the international prostate symptom score and quality of life assessment
89. Toward a clearer definition of confounding
90. Prostate cancer in Rochester, Minnesota (USA), from 1935 to 1989: Increases in incidence related to more complete ascertainment
91. The effects of non-response in a prospective study of cancer: 15-Year follow-up
92. Prospective evaluation plan for randomized trials of prostate cancer screening, for the International Prostate Cancer Screening Trial Evaluation Group